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ABSTRACT
The aim of this study is to evaluate the treatment results of   three dimensional conformal radiotherapy (3DCRT) and androgen dep-
rivation therapy (ADT) in patients with clinically localized prostate cancer (CLPC).  Between June 1998 and December 2011, 577 
patients with the diagnosis of CLPC were treated. ADT was started 3 months prior to radiotherapy (RT). 3DCRT was delivered to 
prostate and the seminal vesicles (SV) to a total dose of 70Gy. Additionally, patients with lymph node (LN) positivity received 50.4Gy 
RT to pelvic LN’s. Median follow up time was 65 months. Five-ten years overall survival (OS), cause specific survival (CSS), PSA 
relapse-free survival (PSA-RFS) and distant metastasis-free survival (DMFS) rates were 92-74%, 97-91%, 77-55% and 94-88%, 
respectively. OS was negatively affected from LN positivity (p< 0.001). In the subgroup of patients with GS≥ 8, there was no signifi-
cant difference between < 1 years and ≥ 1 years of ADT in terms of CSS, PSA-RFS and DMFS. OS was better in patients with < 1 
years of ADT (p= 0.01). Five year OS (p= 0.02), CSS (p= 0.05), PSA-RFS (p= 0.01) and DMFS (p= 0.07) rates were inferior in the 
high risk group patients that used ADT ≥ 1 year. Acute and late RTOG grade III/IV gastrointestinal system toxicity rates were 1.7% 
and 5% and acute and chronic RTOG grade III/IV genitourinary system toxicity rates were 1.4% and 5%, respectively. 3DCRT and 
ADT combination is an effective treatment modality with acceptable toxicities in patients with clinically localized prostate cancer.  
Keywords: Prostate cancer, Conformal radiotherapy, Androgen deprivation therapy
ÖZET
Lokalize Prostat Kanserli Olgularda Üç Boyutlu Konformal Radyoterapi ve Total Androjen Blokajı; Hacettepe Üniversi-
tesi Deneyimi 
Bu çalışmanın amacı, üç boyutlu konformal radyoterapi (3BKRT) ve total androjen blokajı (TAB) Lokalize prostat kanserli olgularımızdaki 
tedavi sonuçlarımızı değerlendirmek. Haziran 1998 ve Aralık 2011 tarihleri arasında lokalize prostat kanseri tanısıyla 577 olgu tedavi 
edildi. TAB tedavisine radyoterapiden (RT) 3 ay sonar başlandı. 3BKRT olarak prostat ve seminal veziküllere toplam 70 Gy uygulandı. 
Ek olarak lenf nodu (LN) tutulumu olan olgularda pelvic LN’larına 50.4 Gy uygulandı. Ortanca izlem süresi 65 aydır. Beş-on yıllık genel 
sağkalım (GS), hastalığa özgü sağkalım (HSS), PSA-relapssız sağkalım (PSA-RFS) ve uzak metastazsız sağkalım (DMFS) oranları 
sırasıyla %92-74, %97-91, %77-55 ve %94-88 bulundu. LN tutulumu GS’ı olumsuz etkilemiştir (p< 0.001). Gleason skoru ≥ 8 olan 
olgularda <1 yıl ile ≥ 1yıl TAB kullanımı arasında HSS, PSA-RFS ve DMFS açısından fark yoktu. Ancak <1 yıl TAB kullananlarda GS 
daha iyiydi (p= 0.01). Yüksek riskli grupta olup ≥ 1yıl TAB kullanan hastalarda 5 yıllık GS (p= 0.02), HSS (p= 0.05), PSA-RFS (p= 0.01) 
ve DMFS (p= 0.07) daha düşük bulundu. Erken ve geç dönem RTOG grad III/IV gastrointestinal sistem toksisite oranları %1.7 ve %5 
bulundu. Erken ve geç dönem RTOG grad III/IV genitoüriner sistem toksisite oranları %1.4 ve %5 bulundu. Lokalize prostat kanseri 
tedavisinde 3BKRT ve TAB tedavisi etkili ve güvenli bir tedavi biçimidir.
Anahtar Kelimeler: Prostat kanseri, Konformal radyoterapi, Androjen deprivasyon tedavisi
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INTRODUCTION
Treatment options for patients with clinically lo-
calized prostate cancer include active surveillance, 
radical prostatectomy or radiotherapy (RT) with 
or without androgen deprivation treatment (ADT). 
The treatment decision is made according to risk 
group of the patient. Although there is no rand-
omized study comparing RT with surgery various 
studies demonstrated that RT is equally effective 
with surgery in the treatment of clinically localized 
prostate cancer. Its effect improves when the dose 
delivered to target is increased. Three dimensional 
conformal radiotherapy (3DCRT) techniques pro-
vide the delivery of higher doses to the target while 
sparing the adjacent normal structures. Addition-
ally, RT and ADT have been shown to improve 
overall survival (OS), PSA relapse free survival 
(PSA-RFS) and distant metastasis free survival 
(DMFS)1-3 compared to RT alone. Thus RT with 
ADT is the standard of care for localized prostate 
cancer in intermediate and high risk patients. 
In this study we aimed to evaluate our treatment 
results in patients with clinically localized prostate 
cancer and identify the factors that had might affect 
the prognosis of the patients. 
PATIENTS AND METHODS
Between June 1998 and June 2011, 577 patients 
with the diagnosis of clinically localized prostate 
adenocarcinoma were treated according to our 
institutional treatment protocol. ADT consisted 
of LHRH analogue plus antiandrogen. ADT was 
started 3 months prior to RT and was continued 
according to the D’Amico risk group of the pa-
tient at the initial diagnosis. The work up studies 
included initial PSA (iPSA), Gleason Score (GS), 
transrectal USG or prostat MRI, abdominopelvic 
computerized tomography (CT) and Tc-99m bone 
scintigraphy.   
Clinical target volume was defined as the prostate 
gland and the entire seminal vesicles (SV). Total 
dose of 70 Gy was delivered to 95% isodose. Thus, 
the dose at the International Commission of Ra-
diation Units and Measurement (ICRU) point was 
73.6 Gy. Twenty nine patients with LN positivity 
received RT to pelvis (50.4 Gy) plus prostate and 
SV (70 Gy). ADT was used ≥ 1 year in 38% of 
the patients. We used 7 fields to deliver the dose to 
the prostate and SV. The doses for adjacent normal 
structures were kept below the tolerance limits of 
each organ; V70<35% and V40<50% for bladder, 
V70<20% and V40<40% for rectum, and V50<5% 
for femoral heads. 
The patients were followed up every 3 months for 
the first 2 years, every 6 months for the next 3 years 
and annually thereafter. Follow up included routine 
physical examination, hemogram, liver function 
tests, PSA and transrectal USG. 
OS, prostate cancer specific survival (CSS), PSA-
RFS, DMFS were assessed in relation  to GS (GS 
2-6, GS 7, GS 8-10), iPSA (PSA≤ 10, 10< PSA≤ 
20, PSA> 20), total percentage of cancer contain-
ing cores (TPC), percent of positive cores (PPC) 
(and perineural invasion (PNI) status. TPC was 
defined as the division of total tumor percentage 
of cancer containing cores with number of total 
cores, multiplied by 100.  PPC was defined as the 
number of biopsy cores with cancer cells divided 
by the total number of cores, multiplied by 100.4 
The patients were grouped as TPC< %50 or ≥%50 
and PPC≤ %50 or >%50. PNI was defined as the 
presence of prostate cancer cells within the spaces 
along the prostatic nerves.5 Patients with T1-2a and 
PSA≤ 10 ng/ml and GS 2-6 were categorized as 
low risk, T2b and 10< PSA≤ 20 and GS 7 as in-
termediate risk and T2c-T4 or PSA> 20 ng/ml and 
GS 8-10 as high risk groups according to D’Amico 
classification.6 Acute and late treatment related 
toxicities were also evaluated using RTOG Acute 
Radiation Morbidity Scoring Criteria and RTOG/
EORTC Late Radiation Morbidity Scoring Schema.
Statistics
SPSS 16.0 (SPSS Inc., Chicago, IL) version was 
used for the statistical analysis. The value of p< 
0.05 was used to determine statistical significance. 
Time to last follow-up, biochemical failure and dis-
tant metastases were calculated starting from the fi-
nal date of 3DCRT. Kaplan-Meier test was used to 
estimate all survival probabilities and hazard rates. 
Evaluation of prognostic factors was done by Log-
rank test for univariate analysis and Cox regression 
for multivariate analysis.  
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RESULTS
Median follow up time was 65 months (range, 
3-169 months). There were 29 patients with lymph 
node (LN) involvement and 8 of them had patho-
logical confirmation of LN positivity. The charac-
teristics of the patients were summarized in Table 
1. PNI status was reported in 520 (90%) patients 
and it was positive in 36.5% of the cases. PPC 
and TPC status were reported in 445(77%) and 
428 (74%) patients, respectively. The percentage 
of patients with PPC> 50% was 40% and TPC≥ 
50% was 25.5%. The characteristics of patients ac-
cording to PPC and TPC status were listed in Table 
2.  Both high PPC and TPC were correlated with 
higher PSA, GS, clinical T stage, higher risk group, 
PNI positivity and increased ADT duration (p< 
0.001). Patients with PPC> %50 and TPC≥ %50 
were tended to be younger than patients with PPC 
≤ %50 and TPC< %50 (p< 0.004 and p<0.001, re-
spectively). PNI positivity didn’t correlate with pa-
tient age (p= 0.28). 
Overall Survival  
Five and 10 years OS rates for entire cohort were 
92% and 74% respectively. According to T stage 
of the patients, there was no difference in OS. Five 
and 7 year OS rates in LN (+) and LN (-) groups 
were 69 and 55% and 97 and 92%, respectively (p< 
0.001). When the patients were analyzed according 
to the GS groups, 5-10 year OS rates were 93 and 
82% in GS ≤ 6 group; 95 and 72% in GS 7 group. 
The patients with GS ≥8 had 5 and 10 year OS rates 
of 87 and 59% that were significantly lower than 
GS ≤ 6 (p= 0.008) and GS 7 (p= 0.027) groups. 
There was no significant difference in OS between 
GS ≤ 6 and GS 7 patient groups (p= 0.89). Five 
and 10 year OS rates in the PSA ≤ 10 ng/ml, PSA 
10-20 ng/ml and PSA > 20 ng/ml groups were 95 
and 84%, 87 and 69%, 91 and 65%, respectively. 
OS rates in the PSA ≤ 10 ng/ml group were sig-
nificantly higher than PSA 10-20 ng/ml (p= 0.002) 
and PSA > 20 ng/ml groups (p= 0.008). However 
there was no difference in OS between the latter 
two groups (p= 0.64). OS rates in low risk patients 
were higher than intermediate (p= 0.005) and high 
risk patients (p= 0.002). PNI (+) patients had 5-10 
year OS rates of 89 and 60% compared to 94 and 
79% in PNI (-) patients (p= 0.06). Presence of TPC 
≥ 50% and PPC > 50% were not a predictor for 
OS (p= 0.9 and p= 0.1, respectively). In the mul-
tivariate analyses only LN positivity significantly 
decreased OS (p= 0.01). 
Prostate Cancer Specific Survival  
Twenty four patients died because of prostate can-
cer. CSS at 5 and 10 years were 97% and 91%. On 
univariate analysis, CSS rates in T2c-T3b groups 
were worse than T1-T2a groups (p= 0.004) but not 
different from T2b patients (p= 0.48). LN positive 
Table 1. The characteristics of 577 patients
Patient characteristics Number (%) 
Median Age (range)  68 years (41-87 years) 
 iPSA  (Ω)              
 ≤ 10 (ng/ml) 209 (36.2)                   
 10-20 (ng/ml)      158 (27.4)             
 > 20(ng/ml)  189 (32.8) 
Gleason Score  (Ω)                   
 ≤ 6 245(42)
    7 166(29)
 ≥  8 166(29)
Clinical T stage  (Ω)  
 T1-T2a 285 (49)                      
 T2b 46(8)                      
 T2c-T4  238 (41) 
PNI   status (Ω) 
 PNI(+) 211(36.5)
 PNI (–) 309 (53.5)
PPC status (Ω)
 PPC  ≤ 50 % 216(37)                  
 PPC  > 50% 229 (40)
TPC status (Ω) 
 TPC < 50%   280(48.5)            
 TPC  ≥ 50% 148 (25.5)
D’Amico Risk Group (Ω)                                   
 Low 97 (16.8)                
 Intermediate 118 (20.5)           
 High 359 (62.2)
 ADT < 1 year  ( Ω) 311 (54)                 
 ADT ≥ 1 year 218 (38) 
Abbreviations:  PPC= percent of tumor positive cores; 
TPC=total percentage of cancer containing cores; iPSA= 
initial prostate specific antigen; PNI= perineural invasion; 
ADT= androgen deprivation therapy;    (Ω) = Not available in 
all patients due to missing data
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patients had worse CSS than LN negative patients 
(p= 0.008). GS, PSA, D’Amico risk groups, TPC, 
PPC and PNI were all significantly associated with 
CSS rates (Table 3 and Figure 1). Patients with GS 
≥ 8 had significantly poor survival than GS 7 (p= 
0.015) and GS ≤ 6 patients (p< 0.001). Survival 
was worse in patients with GS 7 compared to GS ≤ 
6 patients (p= 0.08). CSS in patients with PSA ≤ 10 
ng/ml was better than the subsequent PSA groups 
(p= 0.01 and p< 0.001, respectively). Patients with 
PSA 10-20 ng/ml had better CSS compared to pa-
tients with PSA > 20 ng/ml (p= 0.04). D’Amico 
high risk patients had worse CSS rates than low 
and intermediate risk patients (Table 3). Higher 
TPC and PPC and presence of PNI were all related 
to poor CSS (Figure 1). 
PSA Relapse Free Survival  
One hundred thirty five PSA relapses were report-
ed. Five and 10 years PSA-RFS rates were 77% 
and 55% and median PSA relapse free period was 
54.5 months. We found a significant difference be-
tween T1a-T2a and T2c-T3b groups in favour of 
T1a-T2a group (p= 0.003). Five year PSA-RFS 
rates in the LN positive and LN negative patients 
were 52% and 78%, respectively (p= 0.001). The 
5 and 10 year PSA-RFS rates in three GS groups 
were shown in Table 4. There was no significant 
difference in terms of PSA-RFS between GS ≤ 6 
and GS 7 groups (p= 0.15). Patients with GS ≥ 8 
had significantly worse PSA-RFS than patients 
with either GS ≤ 6 (p < 0.001) or GS 7 (p= 0.002). 
PSA-RFS is affected from the increasing PSA 
levels. 5-10 year PSA-RFS rates in PSA≤ 10 ng/
ml, PSA 10-20 ng/ml and PSA > 20 ng/ml groups 
were; 88% and 74%, 79% and 46%, and 62% and 
40%, respectively. PSA-RFS rate in the PSA > 20 
ng/ml group was significantly worse compared to 
PSA 10-20 ng/ml group (p= 0.007) and PSA ≤ 10 
ng/ml group (p< 0.001).            
Table 2. Patient characteristics by PPC and TPC status
 PPC ≤ %50  PPC>%50 p TPC<%50 TPC≥%50  p 
 n  (%)  n  (%)  n (%)  n  (%)
 
Mean Age 68.3 66.3 <0.004 68.2 65.5 <0.00
iPSA Group     
 ≤10  (ng/ml) 110  (%53) 54 (%24)  132 (%50) 28 (%19) 
 10-20  (ng/ml) 51  (%24) 74 (%33) <0.00 73 (%27) 49 (%33) <0.00
 >20  (ng/ml) 47  (%23) 97 (%43)  62 (%23) 70 (%48) 
Gleason Score     
 ≤6 115  (%53.5) 62 (%27)  149 (%53) 20 (%14) 
 7 63  (%29.3) 69 (%30) <0.00 82 (%29) 43 (%29) <0.00
 ≥8 37  (%17.2) 98  (%43)  49  (%18) 85 (%57) 
 PNI  (+) 53 (%25) 135 (%62) <0.00 88 (%32) 104 (%74) <0.00
 PNI  (–) 160 (%75) 83 (%38)  186 (%68) 37 (%26) 
Clinical Stage     
 T1-T2a 132 (%61) 80 (%35)  168 (%60) 38 (%26) 
 T2b 18 (%9) 18 (%8) <0.00 19 (%7) 13 (%9) <0.00
 T2c-T4 65 (%30) 128 (%57)  93 (%33) 65 (%65) 
D’Amico Risk     
 Low 56 (%26) 15 (%6)  68 (%24) 4 (%3) 
 Intermediate 56 (%26) 32 (%14) <0.00 70 (%25) 12 (%8) <0.00
 High 103 (%48) 182 (%80)  142 (%51) 131 (%89) 
 ADT < 1 year 142 (%70) 89 (%41) <0.00 173 (%65) 53 (%38) 
 ADT ≥ 1 year 62 (%30) 128 (%59)  92 (%35) 87 (%62) <0.00
Abbreviations: PPC= percent of positive cores; TPCC=total percentage of cancer containing cores; iPSA=initial prostate specific 
antigen; PNI= perineural invasion; ADT= androgen deprivation therapy
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Figure 1. Prostate cancer specific survival curves according to (a) initial prostate specific antigen (vPSA), (b) Gleason score (GS), 
(c) D’Amico risk groups, (d) total percentage of cancer containing cores (TPC), (e) percent of positive cores (PPC), (f) perineural 
invasion (PNI) status.
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Five year PSA-RFS rates in the low, intermediate 
and high risk disease groups were 93%, 77% and 
72%, respectively.  Patients in the high risk disease 
group had worse PSA-RFS compared to low risk 
(p< 0.001) and intermediate risk groups (p< 0.001). 
Five-10 year PSA-RFS rates were 60% and 42% 
in the TPC≥ 50% group and 86% and 68% in 
the TPC< 50% group (p< 0.001); 65% and 44% 
in the PPC> 50% group and 89% and 85% in the 
PPC≤50% group, respectively (p< 0.001). PNI sta-
tus was also predictive in terms of PSA-RFS (p= 
0.005).
In the multivariate analysis, iPSA levels (p < 
0.001), LN status (p= 0.001), TPC (p= 0.04) and 
PPC (p= 0.05) were found to be significantly af-
fecting the PSA-RFS.  Additionally, patients with 
LN positive disease had 3.8 times increase in the 
rate of PSA relapse compared to LN negative pa-
tients.  Compared to patients with PSA ≤ 10 ng/
ml; PSA relapse rates were increased 2 times in 
patients with PSA 10-20 ng/ml and 3.5 times in pa-
tients with PSA>20 ng/ml.
Distant Metastasis Free Survival 
There were 37 distant metastases. Fifty percent of 
the patients had no metastases until 65.9 months 
in their follow up. The patients with T2c-T3b had 
more distant metastases compared to T1a-T2a pa-
tients (p= 0.007). Five and 10 year DMFS rates 
in the LN positive and LN negative groups were 
82% and 66.5% and 96% and 95%, respectively 
(p< 0.001). 
Five and 10 year DMFS rates according to GS are 
shown in Table 4. Patients in GS ≥ 8 group had sig-
nificantly worse DMFS compared to patients in GS 
7 (p= 0.001) and GS ≤ 6 groups (p= 0.001). 
Patients with PSA ≤ 10 ng/ml had 5 and 10 year 
DMFS rates of 98% and 97%; patients with PSA 
10-20 ng/ml had 5 and10 year DMFS rates of 95% 
and 90% (p= 0.05). Patients with PSA > 20 ng/ml 
had 5 and 10 years DMFS rates of 89% and 77%, 
respectively. Thus, patients with PSA > 20 ng/ml 
had worse DMFS compared to patients with PSA ≤ 
10 ng/ml (p< 0.001) and PSA 10-20 ng/ml (p=0.05) 
Patients in the low and intermediate risk groups 
did not have significant difference in DMFS (p= 
0.15). However, patients in the high risk group had 
worse DMFS rates compared to intermediate risk 
(p= 0.04) and low risk groups (p= 0.004). 
Five and 10 year DMFS in the TPC ≥ 50% group 
were 88% and 66% compared to 98% in the TPC < 
50% group (p< 0.001).  Five-10 year DMFS in the 
PPC > 50% group were 90%-81% in compared to 
98% in PPC ≤ 50% group (p<0.001).  Patients with 
PNI had worse DMFS than PNI negative patients 
(p= 0.03).
In the multivariate analysis, LN positivity (p= 
0.001) and TPC ≥ %50 (p= 0.05) were shown to 
increase the risk of distant metastasis. Patients with 
GS ≥ 8 had significantly risk of distant metastasis 
compared to patients with GS ≤ 6 (p= 0.01). 
Androgen Deprivation Therapy
Seventy nine percent of patients that used ≥ 1 year 
ADT and 53% of the patients that used < 1 year 
ADT were in the D’Amico high risk group. Al-
though 44% and 47% of the patients that used long 
term ADT were the patients with GS ≥ 8 and PSA > 
20 ng/ml; these rates were only 19% and 24% in < 
1 year ADT used patients,  respectively. Only 11% 
and 61% of the group used ADT for ≥ 2 years and 
≥ 1 year respectively
In the whole group 5 and 10 years OS rates in 
patients that used ADT < 1 year were 99.5% and 
%90.6 compared to 94% and 90% in group of 
patients that used ADT ≥ 1 year (p= 0.03). In the 
subgroup of patients with GS≥ 8, there was no sig-
nificant difference between < 1 years and ≥ 1 years 
of ADT in terms of CSS (p= 0.3), PSA-RFS (p= 
0.15) and DMS (p= 0.4). However OS was better 
in patients with <1 year ADT (Figure 2) (p= 0.01). 
Five and 10 years OS rates were 100% and 53% in 
short term ADT used group; 94% and 66% in long 
term ADT used group. 
In the high risk patients, 5 years OS (p= 0.02), 
CSS (p= 0.05), PSA-RFS (p= 0.01) and DMFS (p= 
0.07) rates were better in patients that used ADT< 
1 years.  
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Toxicity 
RT related acute toxicities were evaluated using 
RTOG Acute Radiation Morbidity criteria and late 
toxicities were evaluated using RTOG/EORTC 
Late Radiation Morbidity scoring schema.7 The 
data about toxicity of gastrointestinal and genito-
urinary systems were available 83% and 85% of 
the patients, respectively. The treatment was well 
tolerated with few grade 3 toxicities. Acute grade 
3 genitourinary and gastrointestinal toxicities were 
reported in 1.4% and 1.7% of cases. Twenty five 
late grade 3 gastrointestinal toxicities were re-
ported (5%). These patients had gastrointestinal 
(GIS) haemorrhage that was required argon laser 
therapy. Only 1 patient had faecal incontinence as 
grade 3 toxicity. Twenty eight (6%) patients had 
RTOG grade 3 genitourinary (GUS) toxicities due 
to radiation stricture that needed minimally inva-
sive procedures (urethral dilation, catheterization, 
transurethral resection of prostate or cystoscopy). 
Twelve of those 28 patients had also urinary in-
continence. Two patients had both GIS and GUS 
Grade 3 toxicity. There was no grade 4 GIS or GUS 
toxicity.
DISCUSSION
The classic prognostic factors for prostate cancer 
are clinical TNM stage, histological grade, GS and 
iPSA.8 These parameters are used to categorize 
patients into some risk groups and decide the ap-
propriate treatment.  In this study we prospectively 
evaluated the treatment results of our patients with 
prostate cancer in terms of OS, CSS, PSA-RFS 
and DMFS in each classical risk status and also we 
studied the other factors like TPC, PPC and PNI 
that have not been routinely used in predictive al-
gorithm. 
It was shown that higher GS is associated with 
greater likelihood of having non-organ confined 
disease, as well as a worse outcome after treatment 
of localized disease.9 In our study, the patients with 
GS ≥ 8 had tendency to be in clinical T2c-T3b 
stage compared to be in clinical T1-2a stage. In GS 
≥ 8 group, the percentage of the patients with PSA 
> 20 ng/ml and with PSA ≤ 10 ng/ml were 45% and 
23%, respectively. These patients had decreased 
rate of OS, CSS, PSA-RFS and DMFS than GS ≤ 6 
and GS 7 patients in our study.          
In LN positive patients, there is evidence to sup-
port attempts to control primary tumor10 and a sys-
temic review concluded that in T3 and/or LN posi-
tive diseases the local therapy is an essential part 
of the optimal treatment.11 When RT is combined 
with ADT in LN positive patients, retrospective 
data suggest excellent biochemical control rates at 
5 and 10 years.12 In RTOG 85-32 trial, LN positive 
patients that received whole pelvic RT (WPRT) 
with combined hormonal treatment, had better 
biochemical control rates at 5 and 9 years com-
pared to WPRT only; 54% and 10% versus 33% 
and 4%, respectively. In our trial, although all of 
the outcomes were worse in LN positive patients 
compared to LN negative counterparts (p= 0.001), 
there were only 5 deaths because of prostate can-
cer in LN positive patients. This may be explained 
by the pelvic RT, long ADT duration and short fol-
low up time in this group of LN positive patients. 
Twenty seven of 29 LN positive patients in our 
study received ADT of ≥1 year.  Observational se-
ries of external RT for LN positive prostate cancer 
Figure 2. Overall survival in Gleason 8-10 patients according 
to the ADT duration. 
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patients have suggested favourable outcomes after 
local therapy, with 10 -year CSS rates in the range 
of 60% and 85%.13,14 In our study due to low num-
bers of LN positive patients, we only report 5 year 
CSS rates of 80%. However we know that more 
patients and more follow-up time are required to 
compare our results with the other trials.
After radical prostatectomy (RP) or RT, there is 
limited data supporting the utility of biopsy sur-
rogates of prostate volume like PPC and TPC for 
prediction of prognosis.15 The relation between 
PPC and biochemical relapse free survival (BFS) 
was explored after ADT16, RP16-18, after WPRT4,19,20 
and brachyterapy.21-24 Although the prognostic sig-
nificance of PPC couldn’t be demonstrated in some 
studies22, Yushen et al reported the prognostic val-
ue of PPC in intermediate and high risk patients 
with regard to CSS, BFS and DMFS.25 Freedland et 
al reported that PPC in biopsy was an independent 
predictor of biochemical relapse and adverse path-
ological findings like higher T stage, higher GS and 
positive surgical margin following RP.26 Briganti et 
al reported that PPC has a predictive value for esti-
mating the lymphatic invasion in addition to PSA, 
clinical T stage and GS.27 In Huang’s study, higher 
PPC was associated with younger age, unfavour-
able risk factors like higher T stage, GS and PSA, 
presence of PNI and more aggressive treatment. 
Association of PPC with distant metastases (DM) 
and correlation of PPC with OS were reported in 
high risk patients.28
More quantitative assessments of biopsy tumor 
volume, such as percentage of tumor volume 
(PCV) have been studied in the context of RP, 
brachytherapy, androgen deprivation therapy, Ex-
ternal RT or combined treatments. These studies all 
suggested that the PCV is a more discriminating 
prognostic variable than the PPC.29
In our study, higher PPC (>50%) and higher TPC 
(≥ 50%) were all correlated with higher GS, PSA, 
T stage, prolonged ADT and presence of PNI (p< 
0.00). Also we found that younger patients had 
tendency to have higher PPC and higher TPC. We 
could not find any relation between the age of pa-
tients and PNI. On univariate analysis we found a 
negative correlation between the extent of cores 
(PPC, TPC and PNI) and CCS, BFS and DMFS. 
On multivariate analysis, we evaluated PPC, TPC, 
PNI, GS, PSA, T stage, risk groups and we ob-
tained significant association between PSA-RFS 
and PPC (p= 0.025) and PSA> 20 ng/ml (p= 0.002) 
patients. When we exclude PPC from the analysis, 
TPC also significantly affects the PSA-RFS (p< 
0.001). We found that TPC≥ 50% patients had 
higher GS, PSA, T  stage,  PNI positivity and are in 
high risk group compared to PPC >%50 patients. 
But why couldn’t we find the predictive value of 
TPC when they were both calculated in same Cox 
analysis? We think that although the patients with 
TPC≥ 50% had poorer factors but could not be 
able to indicate significance in Cox analysis, the 
predictive value of PPC should have been more 
valuable. This is contrary to Vance’s study29 where 
they reported TPC as a prognostic factor for CSS, 
PSA-RFS and DMFS. However in their study PPC 
failed to show an advantage in multivariate analy-
sis. In that study they evaluated the TPC volumes 
in four quartiles including < 2.5%, < 10%, < 25% 
and ≥ 25% TPC. They reported that the NCCN 
high risk patients with TPC< %25 had better clini-
cal outcomes than the high risk group with TPC 
≥ 25%. Similarly the patients with Gleason score 
8-10 and high TPC had worse outcomes than the 
patients with Gleason score 8-10 and low TPC. In 
our study we grouped TPC into TPC < 50% and 
TPC ≥ 50%.  Although we found the similar effect 
of TPC, our large ranges of 50% were probably 
less reliable to make more precise prognostic clas-
sification in comparison to Vance’s study. 
In RTOG 92-02 randomized trial that studied op-
timal duration of ADT, patients received 4 months 
of goserelin acetate and flutamid 2 months before 
and after RT. RT was applied to the prostate and 
pelvic LNs and then prostate was boosted to a total 
dose of 65-70 Gy. Patients then were randomized 
to no further therapy or 2 years goserelin acetate. 
Ten years of updated results of the study showed 
that CSS, PSA-RFS, local control and DMFS were 
all in favour of long term ADT. They also found 
OS advantage specific to GS 8-10 group that used 
long term ADT.30 In EORTC phase III trial RT ver-
sus RT plus ADT was compared. External RT was 
delivered as in RTOG 92-02 study and hormonal 
therapy consisted of goserelin acetate for 3 years 
beginning on the first day of RT. In the updated 
115UHOD   Number: 2   Volume: 25   Year: 2015
International Journal of Hematology and Oncology
results OS, PSA-RFS and DMFS were statistically 
better in the combined therapy than only RT arm.31 
These trials showed that the addition of ADT to 
conventional dose RT resulted in clear improve-
ment in treatment outcomes like OS, BFS and 
DMFS. 
It is also known that a BED of ≥150 Gy resulted in a 
92% freedom from biochemical failure versus 62% 
with BED<150 Gy. The role of ADT with optimal 
dose escalation should be defined. In our study, 
high risk patients that used ADT< 1 years had bet-
ter 5 years OS (p= 0.02), CSS (p= 0.05), PSA-RFS 
(p= 0.01) and DMFS (p= 0.07).  Forty-four percent 
of patients using long term ADT were the patients 
with Gleason score 8-10. When we compared our 
study with RTOG and EORTC trials, the duration 
of hormonal therapy might be shorter and also only 
6% of the patients had pelvic RT. Our RT dose was 
higher than their conventional RT doses. Stock et 
al reported excellent results with 9-12 months of 
ADT combined with high doses of external RT plus 
brachytherapy.32 The role of 6 months of ADT with 
high doses of RT is being investigated in RTOG 
0815 randomized trial.33
Radiation induced proctitis includes symptoms like 
rectal pain, diarrhea, rectal bleeding, increased fre-
quency of movements and urgency. The frequency 
of proctitis after 3D CRT of localized prostate can-
cer is 5-20%.34,35 In a multicenter trial where 450 
patients were treated by 3D CRT, the rate of Grade 
2 and Grade 3 late rectal side effects was reported 
to be 21% and 3%, respectively.36 Zelefsky report-
ed Grade 3 proctitis which required blood transfu-
sion or laser coagulation only in 15 patients (1%). 
It should be considered that they used either inten-
sity modulated radiotherapy (IMRT) or 3DCRT in 
their trial and they stated a significant decline in the 
incidence of Grade ≥ 2 GI toxicities with IMRT.37 
In our study 5% of the patients had Grade 3 late 
rectal toxicity which is higher than Zelefskys’s tri-
al. The possible reason of high Grade 3 toxicity in 
our study may be the RT modality as we treated all 
patients with 3DCRT only. The other treatment re-
lated toxicity is faecal incontinence that is thought 
to be caused by radiation exposure of the ano-rec-
tum. The precise mechanism is not known and the 
relationship between dose volume parameters and 
the severity of faecal incontinence symptoms has 
not been fully established.38 AIRO PROS 0102 trial 
reported a rate of 10.9% Grade ≥1 faecal inconti-
nence.39 In our study, faecal incontinence was re-
ported only in one patient. This low rate may arise 
from the missing data or insufficient feedback be-
cause of socio-cultural level of patients. 
 In this study we reported out treatment results in 
the 3DCRT era. 3DCRT and ADT combination is 
an effective treatment modality with acceptable 
toxicities in patients with prostate cancer. However 
it is known that IMRT has the ability to deliver 
higher radiation doses to the target while sparing 
the normal adjacent structures. Thus we now treat 
prostate cancer patients with IMRT to a total dose 
of 76 Gy. Additionally, it is clear that PPC, TPC 
and PNI are independently important as prognostic 
markers for prostate cancer. These factors should 
also be incorporated to formal risk group classifi-
cation to select the appropriate treatment for pa-
tients.  Using smaller cut off points for TPC and 
PPC may increase the sensibility of these markers 
in assessing the prognosis. 
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